Sanofi part­ners up with dom­i­nant ADC play­er Seagen, dou­bling down on on­col­o­gy in hunt for a bet­ter pipeline

Near­ly 20 years af­ter its first for­ay in­to AD­Cs, Sanofi has come back to dou­ble down on the field with a new al­liance forged with the dom­i­nant play­er in the space.

This morn­ing Sanofi put out word that it had struck a deal with Seagen $SGEN to joint­ly fund the de­vel­op­ment of up to three can­di­dates for can­cer tar­gets, mar­ry­ing Sanofi’s an­ti­bod­ies with the an­ti­body drug con­ju­gate tech that has made Seagen the go-to play­er here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER